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H NMR) spectra were recorded using a Bruker Avance DPX 400 spectrometer at a frequency of 400.2 MHz. Carbon nuclear magnetic resonance ( 13 C NMR) spectra were recorded on a Bruker Avance DPX 400 spectrometer at a frequency of 100 MHz. The spectra are reported as parts per million (ppm) downfield shift using the solvent peak as internal reference. The data are reported as chemical shift (), multiplicity, relative integral, coupling constant (J Hz) and assignment where possible. Low resolution mass spectra were recorded on a Finnigan LCQ Deca ion trap mass spectrometer (ESI). High resolution mass spectra were recorded on a Bruker 7T Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTICR).
HPLC:
Analytical reverse-phase HPLC was performed on a Waters System 2695 separations module with an Alliance series column heater at 30 °C and 2996 photodiode array detector. A Waters Sunfire 5 μm, 2.1 x 150 mm column was used at a flow rate of 0.2 mL min -1 using a mobile phase of 0.1% TFA in water (Solvent A) and 0.1% TFA in acetonitrile (Solvent B) and a linear gradient of 2-50% B over 30 min. The results were analysed with Waters Empower software. Preparative reverse-phase HPLC was performed using a Waters 600 Multisolvent Delivery System and Waters 500 pump with 2996 photodiode array detector or Waters 490E Programmable wavelength detector operating at 254 and 280 nm. A Waters Sunfire 5 μm, 19 x 150 mm column was used at a flow rate of 7 mL min -1 using a mobile phase of 0.1% TFA in water (Solvent A) and 0.1% TFA in acetonitrile (Solvent B) using a linear gradient of 0-100% B over 60 min.
LC-MS was performed on a Thermo Separation Products: Spectra System consisting of p400 Pump and a UV6000LP Photodiode array detector on a Phenomenex Jupiter 5 μm, 2.1 x 150 mm column at a flow rate of 0.2 mL min -1 coupled to a Thermoquest Finnigan LCQ Deca mass spectrometer (ESI) operating in positive mode. Separations involved a mobile phase of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) using a linear gradient of 0-100% B over 15 min.
Material and Methods:
Analytical thin layer chromatography (TLC) was performed on commercially prepared silica plates (Merck Kieselgel 60 0.25 mm F254). Flash column chromatography was performed using 230-400 mesh Kieselgel 60 silica eluting with analytical grade solvents.
TMSOTf was purchased from Aldrich. Commercial materials were used a received unless otherwise noted. Amino acids, coupling reagents and resins were obtained from Novabiochem. Dichloromethane and methanol were distilled from calcium hydride. DMF was obtained as peptide synthesis grade from Auspep or Labscan. All glycosylation reactions were carried out under anhydrous conditions. Note: It has been observed that intermediates 6, 7 and 8 show monosodium adduct, 8 shows monopotassium adduct and final glycopeptide 12 shows disodium adduct. 
S3
To a stirred solution of D-glucosamine hydrochloride (5.00 g, 23.2 mmol) and K2CO3 (9.61 g, 69.6 mmol) in water (50 mL) was added trichloroethoxycarbonyl chloride (5.89 g, 27.8 mmol) dropwise at room temperature. The mixture was left stirring for 1 h before being neutralised with 1 M HCl, concentrated and then lyophilised. Once dry, pyridine (25 mL) and acetic anhydride (15 mL) were added with stirring at 0°C, before being allowed to return to room temperature and stirred for a further 16 h. After, the solution was concentrated under reduced pressure before being purified by flash chromatography (2:1 v/v hexane/ethyl acetate) to yield the title compound 2 (7.37 g 14.1 mmol 61%) as a colourless, amorphous foam. Spectral data in accord with the literature. To a solution of glucopyranoside (0.12 g, 0.20 mmol) and Fmoc-Ser-O t Bu (0.069 g, 0.18 mmol) in dry dichloromethane (2.0 mL) was added dilute TMSOTf (3.6 µL, 20 µmol) in dichloromethane (0.072 mL of 50 µL/mL v/v) with vigorous stirring at room temperature. After one hour the mixture was neutralised with triethylamine (1.2 µL, 0.020 mmol), diluted with toluene, and concentrated under reduced pressure before purification by flash chromatography (3:1 ethyl acetate/toluene) to give the title compound (0.069 g, 0.082 mmol, 41%) as a colourless, amorphous foam.
Table 1, Entry 3
To a solution of glucopyranoside (0.12 g, 0.20 mmol) and Fmoc-Ser-O t Bu (0.077 g, 0.20 mmol) in dry dichloromethane (2.0 mL) was added dilute TMSOTf (3.6 µL, 20 µmol) in dichloromethane (0.072 mL of 50 µL/mL v/v) with vigorous stirring at room temperature. After one hour the mixture was neutralised with triethylamine (1.2 µL, 0.020 mmol), diluted with toluene, and concentrated under reduced pressure before purification by flash chromatography (3:1 ethyl acetate/toluene) to give the title compound (0.076 g, 0.090 mmol, 45%) as a colourless, amorphous foam.
Table 1, Entry 4
To a solution of glucopyranoside (0.12 g, 0.20 mmol) and Fmoc-Ser-O t Bu (0.077 g, 0.20 mmol) in dry dichloromethane (2.0 mL) was prepared and mixed with freshly activated molecular sieves (0.3 g) at -78°C. To it was added dilute TMSOTf (3.6 µL, 20 µmol) in dichloromethane (0.072 mL of 50 µL/mL v/v) with vigorous stirring. The mixture was allowed to slowly reach room temperature over one hour before being neutralised with triethylamine (1.2 µL, 0.020 mmol), diluted with toluene, and concentrated under reduced pressure before purification by flash chromatography (3:1 ethyl acetate/toluene) to give the title compound (0.084 g, 0.10 mmol, 50%) as a colourless, amorphous foam.
Table 1, Entry 5
To a solution of glucopyranoside (0.12 g, 0.20 mmol) and Fmoc-Ser-O t Bu (0.077 g, 0.20 mmol) in dry dichloromethane (2.0 mL) was prepared and mixed with freshly activated molecular sieves (0.3 g) at -78°C. To it was added dilute TMSOTf (0.72 µL, 4.0 µmol) in dichloromethane (0.036 mL of 20 µL/mL v/v) with vigorous stirring. The mixture was allowed to slowly reach room temperature over one hour before being neutralised with triethylamine (0.51 µL, 4.0 µmol), diluted with toluene, and concentrated under reduced pressure before purification by flash chromatography (3:1 ethyl acetate/toluene) to give the title compound (0.118 g, 0.140 mmol, 70%) as a colourless, amorphous foam.
Table 1, Entry 6
To a solution of glucopyranoside (0.12 g, 0.20 mmol) and Fmoc-Ser-O t Bu (0.11 g, 0.30 mmol) in dry dichloromethane (2.0 mL) was prepared and mixed with freshly activated molecular sieves (0.3 g) at - To a solution of Fmoc-Ser(O-GlcNTroc)-OtBu (6) (2.52 g, 2.98 mmol) in acetic anhydride (30.0 mL) was added zinc powder (4.00 g) at room temperature. The mixture was stirred vigorously for 2 hours before being concentrated under reduced pressure and purified by flash chromatography (2:1 ethyl acetate/hexane) to give the title compound 7 (1.65 g, 2.31 mmol, 78 %) as a colourless, amorphous foam. 
Solid-Phase Peptide and Glycopeptide Synthesis
Solid-phase synthesis of peptide and glycopeptide were carried out manually in disposable Torviq polypropylene syringes equipped with Teflon sinter. 
Solid-phase synthesis of model peptide Fmoc-AIPVSR(Pbf)E(OtBu)E(OtBu

OH
Fmoc-protected amino acid Fmoc-Lys(Boc)-OH (937 mg, 2.0 mmol, 10 equiv) was dissolved in dry DCM (9 mL) and DMF (1 mL) mixture. The amino acid solution was cooled to 0 °C before DIC (155 L, 1.0 mmol, 5 equiv) was added. The mixture was allowed to stir for 20 min at 0 °C. The solvent was removed by evaporation under reduced pressure. The resulting symmetrical anhydride was dissolved in DMF (5 mL) and added directly to the resin. A solution of DMAP (2.5 mg, 20 mol, 0.1 equiv) in DMF (1 mL) was added to the resin/amino acid mixture. The solution was allowed to shake for 1 h. The resin was filtered and washed with DMF (5 x 5 mL), DCM (5 x 5 mL) and DMF (5 x 5 mL). The resin was treated with a solution of Ac2O/pyridine (1:9 v/v) for 10 min followed by washing with DMF (5 x 5 mL), DCM (5 x 5 mL) and DMF (5 x 5 mL).
Determination of resin loading:
A solution of piperidine in DMF (4 mL, 10% v/v) was added to the resin, which was shaken for 3 min and procedure repeated. The drained Fmoc deprotection solution was retained in a 10 mL volumetric flask and the resin washed with fresh pieridine in DMF (10% v/v) such that the total volume did not exceed 10 mL. The efficiency of the initial loading was quantitatively determined by measurement of the dibenzofulvene-piperidine adduct using Varian Cary 4000 UV-Vis spectrophotometer ( = 301 nm). Amino acid loading onto the resin was quantitative. The resin was subsequently washed with DMF (10 x 5 mL), DCM (10 x 5 mL), and DMF (10 x 5 mL).
Amino acid coupling:
A solution of protected amino acid (4 equiv), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) (416 mg, 0.8 mmol, 4 equiv), and N-methylmorpholine (NMM) (176 L, 1.6 mmol, 8 equiv) in DMF (2.5 mL) was added to the resin and shaken. After 1 h the resin was washed with DMF (5 x 5 mL), DCM (5 x 5 mL), and DMF (5 x 5 mL).
Capping:
Acetic anhydride/pyridine (1:9 v/v, 2 mL) was added to the resin and shaken. After 3 min the resin was washed with DMF (5 x 5 mL), DCM (5 x 5 mL) and DMF (5 x 5 mL). Capping step was only used during coupling of first four amino acids.
Fmoc Deprotection:
The resin was treated with a solution of piperidine in DMF (4 mL, 10% v/v) and shaken for 3 min. at rt. The procedure was repeated with a fresh portion of deprotection mixture after which the resin was washed with DMF (5 x 5 mL), DCM (5 x 5 mL), and DMF (5 x 5 mL).
Synthetic access to nonapeptide 11 was achieved using Fmoc-SPPS commencing from Wang resin preloaded with Fmoc-Lys(Boc)-OH (10) (Scheme 2). The above steps were repeated in an iterative fashion to assemble the desired peptide on the resin. The appropriate Fmoc-protected amino acids were coupled according to the general amino acid coupling procedure. For coupling of amino acid serine side chain unprotected derivative Fmoc-Ser-OH ( 327.3 mg, 0.8 mmol, 4 equiv) was used. After assembly of nine amino acids on Wang resin dry resin was split into four portions (50 mol each). 
Synthesis of nonapeptide Fmoc-AIPVSREEK-OH (11a) (50 mol scale)
OH
One of the portions of resin (50 mol) was washed thoroughly with DCM (10 x 3 mL) and treated with a solution of TFA/DCM (1:1 v/v, 2 mL) and shaken for 2 hrs at rt. The resin was filtered and washed with TFA/DCM (1:1 v/v, 2 mL). The combined cleavage and washing solutions were evaporated to dryness. The crude peptide was precipitated from cold diethyl ether (10 mL), the supernatant removed and the precipitate dried (quantitative crude yield 62 mg). The resulting residue was purified by preparative HPLC and lyophilised to afford the desired peptide 11a as a fluffy white solid (54.20 mg, 87% yields).
Preparative HPLC: Rt 30.36 min (0-100% B over 60 min,  = 254 nm). 
LCMS:
Glycosylation protocol for synthesis of glycopeptide 12 (50 mol scale)
The glycosylation was performed with dry dichloromethane under an argon atmosphere in Torviq polypropylene syringe. The reaction was carried out on Wang resin using model peptide Fmoc-AIPVSR(Pbf)E(OtBu)E(OtBu)K(Boc) (11). The resin and the glycosyl donor 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)--D-glucopyranosyl trichloroacetimidate (4) (62.5 mg, 0.15 mmol, 3 equiv.) were dried overnight under high vacuum over few pellets of 4Å molecular sieves in the syringe. DCM (4 mL) was injected to allow complete swelling of the resin. After 30 min dilute TMSOTf (0.18 L, 0.001 mmol, 0.02 equiv) in dichloromethane (18 L of 10 L/mL, v/v) was injected and then syringe was agitated at rt for 2 h. Then resin was washed with DMF (5 x 5 mL), DCM (5 x 5 mL) and DMF (5 x 5 mL). The resin was subsequently washed with DCM (10 x 3 mL). A mixture of TFA/DCM (1:1 v/v, 2 mL) was added to the resin and shaken for 2 hrs at rt. The resin was then washed with TFA/DCM (1:1 v/v, 2 x 3 mL), and the combined cleavage and washing solutions were concentrated in vacuo. The crude glycopeptide was suspended in cold diethyl ether (ca. 10 ml). The suspension was transferred to a 50 mL eppendorf tube and centrifuged at 3000 rpm for 5 min. The supernatant ether was carefully decanted and the precipitate was dried under high-vacuum (quantitative crude yield 83 mg). LC-MS analysis of crude product indicated 84% desired glycopeptide along with 16% unreacted peptide. Crude glycopeptide was purified by preparative HPLC and lyophilised to afford the desired glycopeptide 12 as a fluffy white solid (57.4 mg, 67% yield). 
